Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
3/2023 ceased to operate
XTL Biopharmaceuticals
XTL Biopharmaceuticals Overview
XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has three product candidates in clinical development.
XTLs hCDR1 peptide is a compound that works via a novel mechanism for the treatment of systemic lupus erythematosus (SLE). hCDR1 has completed three clinical trials involving more than 400 patients.
Recombinant erythropoietin is a compound being developed by XTL with the potential to help advanced-stage multiple myeloma patients live longer with a better quality of life.
The companys SAM-101 is a proprietary combination of antipsychotic drugs and a known medicinal compound for the treatment of psychotic diseases, with a focus on schizophrenia. SAM-101 has completed a phase 2a study in accordance with the Helsinki guidelines at the Shalvata Medical Center.
XTL Biopharmaceuticals Climate Tech relevance
undefined
Companies you might be interested in
Driven by Finder AI
Latest News
No Data, yet.
Sorry, no content found under this section.
Mar 7, 2017
www.prnewswire.com
XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors
#Investment
Sep 6, 2016
www.prnewswire.com
XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016
#Investment
Nov 15, 2012
www.globes.co.il
XTL acquires 31% stake in Proteologics from Teva
#Acquisition
Nov 3, 2011
www.prnewswire.com
XTL Biopharmaceuticals to Acquire NiCure
#Acquisition
Mar 27, 2011
en.globes.co.il
XTL Bio buys schizophrenia drug developer MinoGuard